BioXcel Therapeutics amends Oaktree-led credit agreement, extends deadline for refinancing deal to Aug. 28

• BioXcel Therapeutics entered a Thirteenth Amendment to its April 19, 2022 Credit Agreement with lenders led by Oaktree Fund Administration.
• The amendment extends a deadline to Aug. 28, 2026 from Aug. 21, 2026 to sign lender-approved definitive transaction agreements.
• Required deal must either repay all loans and other obligations under the Credit Agreement or deliver an alternative capital solutions transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-099900), on August 24, 2026, and is solely responsible for the information contained therein.